Inhibition of the Binding of Interleukin 17A with Interleukin 17A Receptor as a Treatment for Immune System and Inflammation Disorders, Cancer, and Neurodegenerative Diseases.

The invention in this patent application relates to N-(2-amino-2-oxoethyl)heteroarylcarboxamide derivatives, represented herein generally by formula 1. These compounds are inhibitors of the binding of interleukin 17A (IL-17A) with its receptor IL-17RA and may potentially be used for the treatment of diseases or disorders associated with IL-17A activity, which include psoriasis, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis, cancer, and neurodegenerative disorders.